Search

Your search keyword '"Willison, Alice"' showing total 20 results
Start Over Author "Willison, Alice" Search Limiters Full Text
20 results on '"Willison, Alice"'

2. Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

Author

Regner-Nelke, Liesa, Pawlitzki, Marc, Willison, Alice, Rolfes, Leoni, Oezalp, Sinem-Hilal, Nelke, Christopher, Kölsche, Tristan, Korsen, Melanie, Grothe, Matthias, Groppa, Sergiu, Luessi, Felix, Engel, Sinah, Nelles, Gereon, Bonmann, Eckhard, Roick, Holger, Friedrich, Anke, Knorn, Philipp, Landefeld, Harald, Biro, Zoltan, Ernst, Michael, Bayas, Antonios, Menacher, Martina, Akgün, Katja, Kleinschnitz, Christoph, Ruck, Tobias, Ziemssen, Tjalf, Pul, Refik, and Meuth, Sven G.

Published
2022
Full Text
View/download PDF

4. The Use of Nitrosative Stress Molecules as Potential Diagnostic Biomarkers in Multiple Sclerosis

Author

Räuber, Saskia, primary, Förster, Moritz, additional, Schüller, Julia, additional, Willison, Alice, additional, Golombeck, Kristin S., additional, Schroeter, Christina B., additional, Oeztuerk, Menekse, additional, Jansen, Robin, additional, Huntemann, Niklas, additional, Nelke, Christopher, additional, Korsen, Melanie, additional, Fischer, Katinka, additional, Kerkhoff, Ruth, additional, Leven, Yana, additional, Kirschner, Patricia, additional, Kölsche, Tristan, additional, Nikolov, Petyo, additional, Mehsin, Mohammed, additional, Marae, Gelenar, additional, Kokott, Alma, additional, Pul, Duygu, additional, Schulten, Julius, additional, Vogel, Niklas, additional, Ingwersen, Jens, additional, Ruck, Tobias, additional, Pawlitzki, Marc, additional, Meuth, Sven G., additional, Melzer, Nico, additional, and Kremer, David, additional

Published
2024
Full Text
View/download PDF

7. Eculizumab treatment alters the proteometabolome beyond the inhibiton of complement

Author

Nelke, Christopher, primary, Schroeter, Christina B., additional, Stascheit, Frauke, additional, Huntemann, Niklas, additional, Pawlitzki, Marc, additional, Willison, Alice G., additional, Räuber, Saskia, additional, Melzer, Nico, additional, Distler, Ute, additional, Tenzer, Stefan, additional, Stühler, Kai, additional, Roos, Andreas, additional, Meisel, Andreas, additional, Meuth, Sven G., additional, and Ruck, Tobias, additional

Published
2023
Full Text
View/download PDF

8. Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab

Author

Pfeuffer, Steffen, primary, Rolfes, Leoni, additional, Ingwersen, Jens, additional, Pul, Refik, additional, Kleinschnitz, Konstanze, additional, Korsen, Melanie, additional, Räuber, Saskia, additional, Ruck, Tobias, additional, Schieferdecker, Simon, additional, Willison, Alice Grizzel, additional, Aktas, Orhan, additional, Kleinschnitz, Christoph, additional, Hartung, Hans-Peter, additional, Kappos, Ludwig, additional, and Meuth, Sven G., additional

Published
2023
Full Text
View/download PDF

9. Review and meta-analysis of neuropsychological findings in autoimmune limbic encephalitis with autoantibodies against LGI1, CASPR2, and GAD65 and their response to immunotherapy

Author

Mueller, Christoph, Elben, Saskia, Day, Gregory S., Alves, Pedro, Hebert, Julien, Tang-Wai, David F., Holtmann, Olga, Iorio, Raffaele, Perani, Daniela, Titulaer, Maarten J., Hansen, Niels, Bartsch, Thorsten, Johnen, Andreas, Illes, Zslot, Borm, Leah, Willison, Alice G., Wiendl, Heinz, Meuth, Sven G., Kovac, Stjepana, Bölte, Jens, Melzer, Nico, Mueller, Christoph, Elben, Saskia, Day, Gregory S., Alves, Pedro, Hebert, Julien, Tang-Wai, David F., Holtmann, Olga, Iorio, Raffaele, Perani, Daniela, Titulaer, Maarten J., Hansen, Niels, Bartsch, Thorsten, Johnen, Andreas, Illes, Zslot, Borm, Leah, Willison, Alice G., Wiendl, Heinz, Meuth, Sven G., Kovac, Stjepana, Bölte, Jens, and Melzer, Nico

Abstract

Objectives: It is assumed that autoimmune limbic encephalitis (ALE) demonstrates distinct neuropsychological manifestations with differential responses to immunotherapy according to which associated autoantibody (AAB), if any, is identified. Towards investigating whether this is the case, this study aims to summarize respective findings from the primary literature on ALE with AABs binding to cell surface neural antigens and ALE with AABs against intracellular neural antigens. Methods: We chose ALE with AABs against leucine-rich, glioma inactivated protein 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) as the most frequent cell surface membrane antigens, and ALE with AABs to Embryonic Lethal, Abnormal Vision, Like 1 (ELAVL) proteins (anti-Hu) and glutamic acid decarboxylase 65 (GAD65) as the most frequent intracellular neural antigens. The PubMed and Scopus databases were searched on March 1st, 2021 for neuropsychological test and -screening data from patients with ALE of these AAB-types. Findings were reviewed according to AAB-type and immunotherapy status and are presented in a review section and are further statistically evaluated and presented in a meta-analysis section in this publication. Results: Of the 1304 initial hits, 32 studies on ALE with AABs against LGI1, CASPR2, and GAD65 reporting cognitive screening data could be included in a review. In ALE with AABs against LGI1, CASPR2 and GAD65, memory deficits are the most frequently reported deficits. However, deficits in attention and executive functions including working memory, fluency, and psychological function have also been reported. This review shows that ALE patients with AABs against both LGI1 and CASPR2 show higher percentages of neuropsychological deficits compared to ALE patients with AABs against GAD65 before and after initiation of immunotherapy. However, the methodologies used in these studies were heterogenous, and longitudinal studies were not comparable. Moreover, 21 studies in

Published
2023

10. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab

Author

Räuber, Saskia, primary, Willison, Alice, additional, Korsen, Melanie, additional, Kölsche, Tristan, additional, Golombeck, Kristin S., additional, Plaack, Benedikt, additional, Schüller, Julia, additional, Huntemann, Niklas, additional, Rolfes, Leoni, additional, Schroeter, Christina B., additional, Nelke, Christopher, additional, Regner-Nelke, Liesa, additional, Förster, Moritz, additional, Ringelstein, Marius, additional, Barnett, Michael Harry, additional, Hartung, Hans-Peter, additional, Aktas, Orhan, additional, Albrecht, Philipp, additional, Ruck, Tobias, additional, Melzer, Nico, additional, Meuth, Sven G., additional, and Kremer, David, additional

Published
2022
Full Text
View/download PDF

11. Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity

Author

Ruck, Tobias, primary, Barman, Sumanta, additional, Schulte-Mecklenbeck, Andreas, additional, Pfeuffer, Steffen, additional, Steffen, Falk, additional, Nelke, Christopher, additional, Schroeter, Christina B., additional, Willison, Alice, additional, Heming, Michael, additional, Müntefering, Thomas, additional, Melzer, Nico, additional, Krämer, Julia, additional, Lindner, Maren, additional, Riepenhausen, Marianne, additional, Gross, Catharina C., additional, Klotz, Luisa, additional, Bittner, Stefan, additional, Muraro, Paolo A., additional, Schneider-Hohendorf, Tilman, additional, Schwab, Nicholas, additional, Meyer zu Hörste, Gerd, additional, Goebels, Norbert, additional, Meuth, Sven G., additional, and Wiendl, Heinz, additional

Published
2022
Full Text
View/download PDF

13. Gathering Global Perspectives to Establish the Research Priorities and Minimum Data Sets for Degenerative Cervical Myelopathy:Sampling Strategy of the First Round Consensus Surveys of AO Spine RECODE-DCM

Author

Mowforth, Oliver D, Khan, Danyal Z, Wong, Mei Yin, Pickering, George A E, Dean, Lydia, Magee, Joe, Mullarkey, Laura, Hirayama, Yuri, Rihova, Martina, Butler, Max, Stewart, Max, Goulson, Beth, Ahmed, Shahzaib, Fricke, Kai, Popa-Nimigean, Vladimir, Millar, Zack, Venkatesh, Ashwin, Willison, Alice, Senthil, Keerthi, Hazenbiller, Olesja, Sarewitz, Ellen, Sadler, Iwan, Gronlund, Toto, Tetreault, Lindsay, Harrop, James S, Aarabi, Bizhan, Rahimi-Movaghar, Vafa, Kurpad, Shekar N, Guest, James D, Wilson, Jefferson R, Kwon, Brian K, Fehlings, Michael G, McNair, Angus G K, Davies, Benjamin M, and Kotter, Mark R N

Subjects
spondylosis, surveys and questionnaires, Orthopedics and Sports Medicine, Surgery, Neurology (clinical), cervical vertebrae, spinal osteophytosis, spinal cord diseases
Abstract

Study Design Survey. Introduction AO Spine Research Objectives and Common Data Elements for Degenerative Cervical Myelopathy (AO Spine RECODE-DCM) is an international initiative that aims to accelerate knowledge discovery and improve outcomes by developing a consensus framework for research. This includes defining the top research priorities, an index term and a minimum data set (core outcome set and core data elements set – core outcome set (COS)/core data elements (CDE)). Objective To describe how perspectives were gathered and report the detailed sampling characteristics. Methods A two-stage, electronic survey was used to gather and seek initial consensus. Perspectives were sought from spinal surgeons, other healthcare professionals and people with degenerative cervical myelopathy (DCM). Participants were allocated to one of two parallel streams: (1) priority setting or (2) minimum dataset. An email campaign was developed to advertise the survey to relevant global stakeholder individuals and organisations. People with DCM were recruited using the international DCM charity Myelopathy.org and its social media channels. A network of global partners was recruited to act as project ambassadors. Data from Google Analytics, MailChimp and Calibrum helped optimise survey dissemination. Results Survey engagement was high amongst the three stakeholder groups: 208 people with DCM, 389 spinal surgeons and 157 other healthcare professionals. Individuals from 76 different countries participated; the United States, United Kingdom and Canada were the most common countries of participants. Conclusion AO Spine RECODE-DCM recruited a diverse and sufficient number of participants for an international PSP and COS/CDE process. Whilst PSP and COS/CDE have been undertaken in other fields, to our knowledge, this is the first time they have been combined in one process.

Published
2021

14. Platelet Inhibition by Low-Dose Acetylsalicylic Acid Reduces Neuroinflammation in an Animal Model of Multiple Sclerosis

Author

Vogelsang, Anna, primary, Eichler, Susann, additional, Huntemann, Niklas, additional, Masanneck, Lars, additional, Böhnlein, Hannes, additional, Schüngel, Lisa, additional, Willison, Alice, additional, Loser, Karin, additional, Nieswandt, Bernhard, additional, Kehrel, Beate E., additional, Zarbock, Alexander, additional, Göbel, Kerstin, additional, and Meuth, Sven G., additional

Published
2021
Full Text
View/download PDF

17. Gathering Global Perspectives to Establish the Research Priorities and Minimum Data Sets for Degenerative Cervical Myelopathy: Sampling Strategy of the First Round Consensus Surveys of AO Spine RECODE-DCM

Author

Davies, Benjamin M., Kwon, Brian K., Fehlings, Michael G., Kotter, Mark R. N., Mowforth, Oliver D., Khan, Danyal Z, Wong, Mei Yin, Pickering, George A. E., Dean, Lydia, Magee, Joe, Mullarkey, Laura, Hirayama, Yuri, Rihova, Martina, Butler, Max, Stewart, Max, Goulson, Beth, Ahmed, Shahzaib, Fricke, Kai, Popa-Nimigean, Vladimir, Millar, Zack, Venkatesh, Ashwin, Willison, Alice, Senthil, Keerthi, Hazenbiller, Olesja, Sarewitz, Ellen, Sadler, Iwan, Gronlund, Toto, Tetreault, Lindsay, Harrop, James S., Aarabi, Bizhan, Rahimi-Movaghar, Vafa, Kurpad, Shekar N, Guest, James D., Wilson, Jefferson R., Kwon, Brian K., Fehlings, Michael G., McNair, Angus G.K., Davies, Benjamin M., and Kotter, Mark R.N.

Abstract

Study Design Survey.Introduction AO Spine Research Objectives and Common Data Elements for Degenerative Cervical Myelopathy (AO Spine RECODE-DCM) is an international initiative that aims to accelerate knowledge discovery and improve outcomes by developing a consensus framework for research. This includes defining the top research priorities, an index term and a minimum data set (core outcome set and core data elements set – core outcome set (COS)/core data elements (CDE)).Objective To describe how perspectives were gathered and report the detailed sampling characteristics.Methods A two-stage, electronic survey was used to gather and seek initial consensus. Perspectives were sought from spinal surgeons, other healthcare professionals and people with degenerative cervical myelopathy (DCM). Participants were allocated to one of two parallel streams: (1) priority setting or (2) minimum dataset. An email campaign was developed to advertise the survey to relevant global stakeholder individuals and organisations. People with DCM were recruited using the international DCM charity Myelopathy.organd its social media channels. A network of global partners was recruited to act as project ambassadors. Data from Google Analytics, MailChimp and Calibrum helped optimise survey dissemination.Results Survey engagement was high amongst the three stakeholder groups: 208 people with DCM, 389 spinal surgeons and 157 other healthcare professionals. Individuals from 76 different countries participated; the United States, United Kingdom and Canada were the most common countries of participants.Conclusion AO Spine RECODE-DCM recruited a diverse and sufficient number of participants for an international PSP and COS/CDE process. Whilst PSP and COS/CDE have been undertaken in other fields, to our knowledge, this is the first time they have been combined in one process.

Published
2022
Full Text
View/download PDF

19. Gathering Global Perspectives to Establish the Research Priorities and Minimum Data Sets for Degenerative Cervical Myelopathy: Sampling Strategy of the First Round Consensus Surveys of AO Spine RECODE-DCM.

Author

Mowforth, Oliver D., Khan, Danyal Z, Wong, Mei Yin, Pickering, George A. E., Dean, Lydia, Magee, Joe, Mullarkey, Laura, Hirayama, Yuri, Rihova, Martina, Butler, Max, Stewart, Max, Goulson, Beth, Ahmed, Shahzaib, Fricke, Kai, Popa-Nimigean, Vladimir, Millar, Zack, Venkatesh, Ashwin, Willison, Alice, Senthil, Keerthi, and Hazenbiller, Olesja

Published
2022
Full Text
View/download PDF

20. Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.

Author

Pfeuffer S, Rolfes L, Ingwersen J, Pul R, Kleinschnitz K, Korsen M, Räuber S, Ruck T, Schieferdecker S, Willison AG, Aktas O, Kleinschnitz C, Hartung HP, Kappos L, and Meuth SG

Subjects
Humans, Male, United States, Adult, Female, Prospective Studies, Treatment Outcome, Antilymphocyte Serum, Recurrence, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis drug therapy
Abstract

Background and Objectives: B cell-depleting antibodies were proven as effective strategy for the treatment of relapsing multiple sclerosis (RMS). The monoclonal antibody ocrelizumab was approved in 2017 in the United States and in 2018 in the European Union, but despite proven efficacy in randomized, controlled clinical trials, its effectiveness in the real-world setting remains to be fully elucidated. In particular, most study patients were treatment naive or switched from injectable therapies, whereas oral substances or monoclonal antibodies made up >1% of previous treatments., Methods: We evaluated ocrelizumab-treated patients with RMS enrolled in the prospective cohorts at the University Hospitals Duesseldorf and Essen, Germany. Epidemiologic data at baseline were compared, and Cox proportional hazard models were applied to evaluate outcomes., Results: Two hundred eighty patients were included (median age: 37 years, 35% male patients). Compared with using ocrelizumab as a first-line treatment, its use as a third-line therapy increased hazard ratios (HRs) for relapse and disability progression, whereas differences between first- vs second-line and second- vs third-line remained smaller. We stratified patients according to their last previous disease-modifying treatment and here identified fingolimod (FTY) (45 patients, median age 40 years, 33% male patients) as a relevant risk factor for ongoing relapse activity despite 2nd-line (HR: 3.417 [1.007-11.600]) or 3rd-line (HR: 5.903 [2.489-13.999]) ocrelizumab treatment, disability worsening (2nd line: HR: 3.571 [1.013-12.589]; 3rd line: HR: 4.502 [1.728-11.729]), and occurrence of new/enlarging MRI lesions (2nd line: HR: 1.939 [0.604-6.228]; 3rd line: HR: 4.627 [1.982-10.802]). Effects were persistent throughout the whole follow-up. Neither peripheral B-cell repopulation nor immunoglobulin G levels were associated with rekindling disease activity., Discussion: Our prospectively collected observational data suggest suboptimal effectiveness of ocrelizumab in patients switching from FTY compared with those switching from other substances or having been treatment naive. These findings support previous studies indicating abated effectiveness of immune cell-depleting therapies following FTY treatment in patients with RMS., Classification of Evidence: This study provides Class IV evidence that for patients with RMS, previous treatment with FTY compared with previous treatment with other immunomodulating therapies decreases the effectiveness of ocrelizumab., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results